Multicenter Study Evaluating the Performance of the Assay of Anti-hinge Region Antibodies in the Diagnosis of Progressive Forms of IgA Nephropathy
NCT ID: NCT02526966
Last Updated: 2017-01-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
68 participants
INTERVENTIONAL
2012-03-31
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This research project constitutes the first step in validating these antibodies biomarker of IgA nephropathy and its main objective is to study the performance of the blood levels of anti-hinge region antibodies in the diagnosis of progressive forms of histologically IgA nephropathy as defined by the Renal Risk Absolute.
The secondary objectives of this project are to establish a bio-collection that will allow us to search for other prognostic factors (genetic, cellular and serum) of IgA nephropathy and to evaluate the performance of Renal Absolute risk by integrating Oxford score, the new international histological classification.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Interest of Follicular Helper Lymphocytes / Regulatory Follicular Helper Lymphocytes Ratio in IgA Nephropathy
NCT05791162
Study of the IgA Repertoire During IgA Deposition Nephropathy.
NCT04092491
IgA Nephropathy, Lymphocyte Homing and IgA Class Switch
NCT01775527
Immune System Related Kidney Disease
NCT00001979
Identification and Characterisation of IgA With Nephritogenic Potential in IgA Deposition Nephropathies (Rep-IgAN)
NCT07295808
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patient with primitive form of IgA nephropathy
blood sample
dosage of anti-hinge region antibodies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood sample
dosage of anti-hinge region antibodies
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of a primitive form of IgA nephropathy histologically proven
Exclusion Criteria
* Less than 5 glomeruli present on renal biopsy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Saint Etienne
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christophe MARIAT, MD PhD
Role: PRINCIPAL_INVESTIGATOR
CHU de SAINT-ETIENNE
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CH d'ANNECY
Annecy, , France
CH d'ANNONAY
Annonay, , France
CH de BOURG EN BRESSE
Bourg-en-Bresse, , France
CH de CHAMBERY
Chambéry, , France
CHU de CLERMONT-FERRAND
Clermont-Ferrand, , France
CHU de DIJON
Dijon, , France
CHU de GRENOBLE
Grenoble, , France
CH du PUY EN VELAY
Le Puy-en-Velay, , France
Hôpital Edouard. HERRIOT
Lyon, , France
Centre Hospitalier de Lyon Sud
Pierre-Bénite, , France
CH de ROANNE
Roanne, , France
Hôpitaux Drome Nord
Romans, , France
CHU de SAINT-ETIENNE
Saint-Etienne, , France
CH de VALENCE
Valence, , France
Clinique du TONKIN
Villeurbanne, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-A00860-41
Identifier Type: OTHER
Identifier Source: secondary_id
1108060
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.